Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2024International Journal of Molecular SciencesOpen Access

Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration

View Full Paper
Ask AI
Bookmark
Share

Authors

PTPradeep TyagiJHJason HafronJKJonathan L. Kaufman

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tyagi et al. (2024) studied this question.

synapsesocial.com/papers/68e6c1bdb6db643587640970https://doi.org/10.3390/ijms25094945
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines2026 · 1 citations
  2. 2Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies2025
  3. 3Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer2026 · 1 citations
  4. 4Immunotherapy in Bladder Cancer: A Systematic Review of Clinical Trials and Therapeutic Advances2025
  5. 5The immunotherapy paradox in high-risk non-muscle-invasive bladder cancer: A tale of three trials2026